<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DOXORUBICIN HYDROCHLORIDE- doxorubicin hydrochloride injection, solution </strong><br>Pfizer Laboratories Div Pfizer Inc<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use DOXORUBICIN HYDROCHLORIDE safely and effectively. See full prescribing information for DOXORUBICIN HYDROCHLORIDE.<br><br>DOXORUBICIN HYDROCHLORIDE injection, for intravenous use<br>Initial U.S. Approval: 1974</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">CARDIOMYOPATHY</span>, SECONDARY MALIGNANCIES, <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">EXTRAVASATION</span> AND TISSUE <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">NECROSIS</span>, and SEVERE <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">MYELOSUPPRESSION</span></span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul class="Disc">
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span>: Myocardial damage can occur with doxorubicin HCl with incidences from 1% – 20% for cumulative doses from 300 mg/m<span class="Sup">2 </span>to 500 mg/m<span class="Sup">2</span> when doxorubicin HCl is administered every 3 weeks. The risk of <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> is further increased with concomitant cardiotoxic therapy. Assess left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> (LVEF) before and regularly during and after treatment with doxorubicin HCl. (<a href="#S5.1">5.1</a>) </span></li>
<li><span class="Bold">Secondary Malignancies: Secondary acute myelogenous <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> (AML) and <span class="product-label-link" type="condition" conceptid="138994" conceptname="Myelodysplastic syndrome">myelodysplastic syndrome</span> (MDS) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin HCl. (<a href="#S5.2">5.2</a>)</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> and Tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">Necrosis</span>: <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> of doxorubicin HCl can result in severe local tissue injury and <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> requiring wide excision and skin grafting.  Immediately terminate the drug, and apply ice to the affected area. (<a href="#S5.3">5.3</a>)</span></li>
<li><span class="Bold">Severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> resulting in serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span>, requirement for transfusions, hospitalization, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur. (<a href="#S5.4">5.4</a>)</span></li>
</ul>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">CARDIOMYOPATHY</span>, SECONDARY MALIGNANCIES, <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">EXTRAVASATION</span> AND TISSUE <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">NECROSIS</span>, and SEVERE <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">MYELOSUPPRESSION</span></span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul class="Disc">
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span>: Myocardial damage can occur with doxorubicin HCl with incidences from 1% – 20% for cumulative doses from 300 mg/m<span class="Sup">2 </span>to 500 mg/m<span class="Sup">2</span> when doxorubicin HCl is administered every 3 weeks. The risk of <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> is further increased with concomitant cardiotoxic therapy. Assess left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> (LVEF) before and regularly during and after treatment with doxorubicin HCl. (<a href="#S5.1">5.1</a>) </span></li>
<li><span class="Bold">Secondary Malignancies: Secondary acute myelogenous <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> (AML) and <span class="product-label-link" type="condition" conceptid="138994" conceptname="Myelodysplastic syndrome">myelodysplastic syndrome</span> (MDS) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin HCl. (<a href="#S5.2">5.2</a>)</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> and Tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">Necrosis</span>: <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> of doxorubicin HCl can result in severe local tissue injury and <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> requiring wide excision and skin grafting.  Immediately terminate the drug, and apply ice to the affected area. (<a href="#S5.3">5.3</a>)</span></li>
<li><span class="Bold">Severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> resulting in serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span>, requirement for transfusions, hospitalization, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur. (<a href="#S5.4">5.4</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: </p>
<ul class="Disc">
<li> as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (<a href="#S1.1">1.1</a>).</li>
<li> for the treatment of: <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphoblastic leukemia</span>, <span class="product-label-link" type="condition" conceptid="4073533" conceptname="Acute myeloid leukemia">acute myeloblastic leukemia</span>, Hodgkin <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, Non-Hodgkin <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, metastatic breast cancer, metastatic Wilms' tumor, metastatic <span class="product-label-link" type="condition" conceptid="4333766" conceptname="Neuroblastoma">neuroblastoma</span>, metastatic soft tissue <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span>, metastatic bone <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcomas</span>, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (<a href="#S1.2">1.2</a>).</li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li> Single agent: 60 to 75 mg/m<span class="Sup">2</span> given intravenously every 21 days (<a href="#S2.1">2.1</a>).</li>
<li> In combination therapy: 40 to 75 mg/m<span class="Sup">2</span> given intravenously every 21 to 28 days (<a href="#S2.1">2.1</a>).</li>
<li> Discontinue doxorubicin HCl in patients who develop signs or symptoms of <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> (<a href="#S2.2">2.2</a>).</li>
<li> Reduce dose in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (<a href="#S2.2">2.2</a>).</li>
</ul></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Doxorubicin HCl injection: Vials contain 10 mg/5 mL, 20 mg/10 mL, 50 mg/25 mL, 150 mg/75 mL, and 200 mg/100 mL as a solution (<a href="#S3">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li> Severe myocardial insufficiency (<a href="#S4">4</a>)</li>
<li> Recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (<a href="#S4">4</a>)</li>
<li> Severe persistent drug-induced <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> (<a href="#S4">4</a>)</li>
<li> Severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (<a href="#S4">4</a>)</li>
<li> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to doxorubicin HCl (<a href="#S4">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li> Radiation-induced toxicity can be increased by the administration of doxorubicin HCl. Radiation recall can occur in patients who receive doxorubicin HCl after prior radiation therapy (<a href="#S5.7">5.7</a>).</li>
<li> Embryofetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of potential risk to the fetus (<a href="#S5.8">5.8</a>).</li>
</ul></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta">The most common (&gt;10%) adverse drug reactions are <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (<a href="#S6.1">6.1</a>).<br><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch<span class="Italics">.</span></span> </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Avoid concurrent use of doxorubicin HCl with inhibitors and inducers of CYP3A4, CYP2D6, and/or P-gp (<a href="#S7.1">7.1</a>).</li>
<li>Do not administer doxorubicin HCl in combination with trastuzumab due to increased risk of cardiac dysfunction (<a href="#S5.1">5.1</a>, <a href="#S7.2">7.2</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li> Nursing Mothers: Discontinue drug or nursing taking into consideration importance of drug to mother (<a href="#S8.3">8.3</a>).</li>
<li> Pediatric Use: Recommend long-term follow-up cardiac evaluations due to risk of delayed cardiotoxicity (<a href="#S8.4">8.4</a>).</li>
<li> Females and Males of Reproductive Potential: May impair fertility. Counsel female and male patients on pregnancy planning and prevention (<a href="#S8.6">8.6</a>).</li>
</ul></div>
<div><div>
<div></div>
<div></div>
</div></div>
<div></div>
<div></div>
<div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 2/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNING: <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">CARDIOMYOPATHY</span>, SECONDARY MALIGNANCIES, <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">EXTRAVASATION</span> AND TISSUE <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">NECROSIS</span>, and SEVERE <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">MYELOSUPPRESSION</span></span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1	Adjuvant Breast Cancer</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Other Cancers</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1		Recommended Dose</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Dose Modifications</a></h2>
<h2><a href="#section-2.3" class="toc">2.3	Preparation and Administration</a></h2>
<h2><a href="#section-2.4" class="toc">2.4	Procedures for Proper Handling and Disposal</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	<span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span> and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2	Secondary Malignancies</a></h2>
<h2><a href="#section-5.3" class="toc">5.3	<span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> and Tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">Necrosis</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4	Severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5	Use in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6	<span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor Lysis Syndrome</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7	Radiation Sensitization and Radiation Recall</a></h2>
<h2><a href="#section-5.8" class="toc">5.8	Embryofetal Toxicity</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trial Experience in Breast Cancer</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	Effect of CYP3A4 Inhibitors, Inducers and P-gp</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	Trastuzumab</a></h2>
<h2><a href="#section-7.3" class="toc">7.3	Paclitaxel</a></h2>
<h2><a href="#section-7.4" class="toc">7.4	Dexrazoxane</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 	6-Mercaptopurine</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6	Females and Males of Reproductive Potential</a></h2>
<h2><a href="#section-8.6" class="toc">8.7	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNING: <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">CARDIOMYOPATHY</span>, SECONDARY MALIGNANCIES, <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">EXTRAVASATION</span> AND TISSUE <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">NECROSIS</span>, and SEVERE <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">MYELOSUPPRESSION</span></span></h1>
<ul class="Disc">
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span>: Myocardial damage, including <span class="product-label-link" type="condition" conceptid="4108245" conceptname="Acute left ventricular failure">acute left ventricular failure</span> can occur with doxorubicin HCl. The risk of <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> is proportional to the cumulative exposure with incidence rates from 1% – 20% for cumulative doses ranging from 300 mg/m<span class="Sup">2</span> to 500 mg/m<span class="Sup">2</span> when doxorubicin HCl is administered every 3 weeks. The risk of <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> is further increased with concomitant cardiotoxic therapy. Assess LVEF before and regularly during and after treatment with doxorubicin HCl <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</span></li>
<li><span class="Bold">Secondary Malignancies: Secondary acute myelogenous <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> (AML) and <span class="product-label-link" type="condition" conceptid="138994" conceptname="Myelodysplastic syndrome">myelodysplastic syndrome</span> (MDS) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin HCl <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>.</span></li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> and Tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">Necrosis</span>: <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> of doxorubicin HCl can result in severe local tissue injury and <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> requiring wide excision of the affected area and skin grafting. Immediately terminate the drug and apply ice to the affected area <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>.</span></li>
<li><span class="Bold">Severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> resulting in serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span>, requirement for transfusions, hospitalization, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>.</span></li>
</ul>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1	Adjuvant Breast Cancer</h2>
<p class="First">Doxorubicin HCl is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Other Cancers</h2>
<p class="First">Doxorubicin HCl is indicated for the treatment of</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphoblastic leukemia</span></li>
<li><span class="product-label-link" type="condition" conceptid="4073533" conceptname="Acute myeloid leukemia">acute myeloblastic leukemia</span></li>
<li>Hodgkin <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span></li>
<li>non-Hodgkin <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> (NHL)</li>
<li>metastatic breast cancer</li>
<li>metastatic Wilms' tumor</li>
<li>metastatic <span class="product-label-link" type="condition" conceptid="4333766" conceptname="Neuroblastoma">neuroblastoma</span></li>
<li>metastatic soft tissue <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span></li>
<li>metastatic bone <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span></li>
<li>metastatic ovarian carcinoma</li>
<li>metastatic transitional cell bladder carcinoma</li>
<li>metastatic thyroid carcinoma</li>
<li>metastatic gastric carcinoma</li>
<li>metastatic bronchogenic carcinoma</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1		Recommended Dose</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.1"></a><p></p>
<p class="First"><span class="Italics">Adjuvant Breast Cancer</span></p>
<p>The recommended dose of doxorubicin HCl is 60 mg/m<span class="Sup">2 </span>administered as an intravenous bolus on day 1 of each 21-day treatment cycle, in combination with cyclophosphamide, for a total of four cycles <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.2"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">Metastatic Disease</span>, <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemia</span>, or <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span></span></p>
<ul class="Disc">
<li>The recommended dose of doxorubicin HCl when used as a single agent is 60 to 75 mg/m<span class="Sup">2</span> intravenously every 21 days.</li>
<li>The recommended dose of doxorubicin HCl, when administered in combination with other chemotherapy drugs, is 40 to 75 mg/m<span class="Sup">2</span> intravenously every 21 to 28 days.</li>
<li>Consider use of the lower doxorubicin dose in the recommended dose range or longer intervals between cycles for heavily pretreated patients, elderly patients, or obese patients.</li>
<li>Cumulative doses above 550 mg/m<span class="Sup">2</span> are associated with an increased risk of <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]. </span>
</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Dose Modifications</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.1"></a><p></p>
<p class="First"><span class="Italics">Cardiac Impairment</span></p>
<p>Discontinue doxorubicin in patients who develop signs or symptoms of <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2.2"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>Doxorubicin HCl is contraindicated in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class C or serum bilirubin &gt;5.0 mg/dL)<span class="Italics"> [see <a href="#S4">Contraindications (4)</a>].</span></p>
<p>Decrease the dose of doxorubicin HCl in patients with elevated serum total bilirubin concentrations as follows:</p>
<table width="75%">
<col align="center" valign="middle" width="50%">
<col align="center" valign="middle" width="50%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Serum bilirubin concentration</th>
<th class="Rrule" align="center">Doxorubicin HCl Dose reduction</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">1.2 – 3.0 mg/dL</td>
<td class="Rrule" align="center">50 %</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">3.1 – 5.0 mg/dL</td>
<td class="Rrule" align="center">75 %</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">greater than 5.0 mg/dL</td>
<td class="Rrule" align="center">Do not initiate doxorubicin HCl<br>Discontinue doxorubicin HCl</td>
</tr>
</tbody>
</table>
<p><span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a> and <a href="#S8.7">Use in Specific Population (8.7)</a>]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3	Preparation and Administration</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.1"></a><p></p>
<p class="First"><span class="Italics">Preparation for Continuous Intravenous Infusion </span></p>
<p>Dilute doxorubicin HCl solution in 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP.  Protect from light following preparation until completion of infusion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.2"></a><p></p>
<p class="First"><span class="Italics">Administration</span></p>
<p>Visually inspect parenteral drug products for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard if the solution is discolored, cloudy, or contains particulate matter.</p>
<p>Storage of vials of Doxorubicin HCl Injection under refrigerated conditions can result in the formation of a gelled product. Place gelled product at room temperature [15º to 30ºC (59º to 86ºF)] for 2 to 4 hours to return the product to a slightly viscous, mobile solution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.3"></a><p></p>
<p class="First"><span class="Italics">Administration by Intravenous Injection</span>:</p>
<ul class="Disc">
<li>Administer doxorubicin HCl as an intravenous injection through a central intravenous line or a secure and free-flowing peripheral venous line containing 0.9% Sodium Chloride Injection, USP, 0.45% Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP.</li>
<li>Administer doxorubicin HCl intravenously over 3 to 10 minutes. Decrease the rate of doxorubicin HCl administration if erythematous streaking along the vein proximal to the site of infusion or <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">facial flushing</span> occur.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.4"></a><p></p>
<p class="First"><span class="Italics">Administration by Continuous Intravenous Infusion:</span></p>
<ul class="Disc">
<li>Infuse only through a central catheter. Decrease the rate of doxorubicin HCl administration if erythematous streaking along the vein proximal to the site of infusion or <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">facial flushing</span> occur.</li>
<li>Protect from light from preparation for infusion until completion of infusion.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.5"></a><p></p>
<p class="First"><span class="Italics">Management of Suspected <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span></span></p>
<p>Discontinue doxorubicin HCl for burning or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> sensation or other evidence indicating peri-venous infiltration or <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>. Manage confirmed or suspected <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> as follows:</p>
<ul class="Disc">
<li>Do not remove the needle until attempts are made to aspirate extravasated fluid.</li>
<li>Do not flush the line.</li>
<li>Avoid applying pressure to the site.</li>
<li>Apply ice to the site intermittently for 15 min 4 times a day for 3 days.</li>
<li>If the <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> is in an extremity, elevate the extremity.</li>
<li>In adults, consider administration of dexrazoxane <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.6"></a><p></p>
<p class="First"><span class="Italics">Incompatibility with Other Drugs</span></p>
<p>Do not admix doxorubicin HCl with other drugs. If doxorubicin HCl is mixed with heparin or fluorouracil a precipitate may form. Avoid contact with alkaline solutions which can lead to hydrolysis of doxorubicin HCl.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4	Procedures for Proper Handling and Disposal</h2>
<p class="First">Handle and dispose of doxorubicin HCl consistent with recommendations for the handling and disposal of hazardous drugs.<span class="Sup">1</span></p>
<p>Treat accidental contact with the skin or eyes immediately by copious lavage with water, or soap and water, or sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> solution. Do not abrade the skin by using a scrub brush. Seek medical attention.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Doxorubicin Hydrochloride Injection: Vials contain 10 mg/5 mL, 20 mg/10 mL, 50 mg/25 mL, 150 mg/75 mL, and 200 mg/100 mL doxorubicin hydrochloride as a clear red solution.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Doxorubicin HCl is contraindicated in patients with:</p>
<ul class="Disc">
<li>Severe myocardial insufficiency <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>
</li>
<li>Recent (occurring within the past 4–6 weeks) <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>
</li>
<li>Severe persistent drug-induced <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>
</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (defined as Child Pugh Class C or serum bilirubin level greater than 5 mg/dL) <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>
</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to doxorubicin HCl including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span><span class="Italics"> [see <a href="#S6.2">Adverse Reactions (6.2)</a>]</span>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	<span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span> and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.1"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span></span></p>
<p>Doxorubicin HCl can result in myocardial damage, including <span class="product-label-link" type="condition" conceptid="4108245" conceptname="Acute left ventricular failure">acute left ventricular failure</span>. The risk of <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> is generally proportional to the cumulative exposure. Include prior doses of other anthracyclines or anthracenediones in calculations of total cumulative dosage for doxorubicin HCl. <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span> may develop during treatment or up to several years after completion of treatment and can include decrease in LVEF and signs and symptoms of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (CHF). The probability of developing <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> is estimated to be 1 to 2% at a total cumulative dose of 300 mg/m<span class="Sup">2</span> of doxorubicin HCl, 3 to 5% at a dose of 400 mg/m<span class="Sup">2</span>, 5 to 8% at a dose of 450 mg/m<span class="Sup">2</span>, and 6 to 20% at a dose of 500 mg/m<span class="Sup">2</span>, when doxorubicin HCl is administered every 3 weeks. There is an additive or potentially synergistic increase in the risk of <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> in patients who have received radiotherapy to the mediastinum or concomitant therapy with other known cardiotoxic agents such as cyclophosphamide and trastuzumab.</p>
<p><span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">Pericarditis</span> and <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> have also been reported during or following doxorubicin HCl treatment.</p>
<p>Assess left ventricular cardiac function (e.g., MUGA or echocardiogram) prior to initiation of doxorubicin HCl, during treatment to detect acute changes, and after treatment to detect delayed cardiotoxicity. Increase the frequency of assessments as the cumulative dose exceeds 300 mg/m<span class="Sup">2</span>. Use the same method of assessment of LVEF at all time points <span class="Italics">[see <a href="#S8.4">Use in Specific Populations (8.4)</a>]</span>. </p>
<p>Consider the use of dexrazoxane to reduce the incidence and severity of <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> due to doxorubicin HCl administration in patients who have received a cumulative doxorubicin HCl dose of 300 mg/m<span class="Sup">2 </span>and who will continue to receive doxorubicin HCl.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1.2"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span></span></p>
<p>Doxorubicin HCl can result in <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, including life-threatening <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, during or within a few hours after doxorubicin HCl administration and at any time point during treatment. <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachyarrhythmias</span>, including <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">sinus tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">premature ventricular contractions</span>, and <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, as well as <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> may occur. Electrocardiographic changes including non-specific ST-T wave changes, atrioventricular and bundle-branch block can also occur. These electrocardiographic changes may be transient and self-limited and may not require dose-modifications of doxorubicin HCl.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	Secondary Malignancies</h2>
<p class="First">The risk of developing secondary acute myelogenous <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> (AML) and <span class="product-label-link" type="condition" conceptid="138994" conceptname="Myelodysplastic syndrome">myelodysplastic syndrome</span> (MDS) is increased following treatment with doxorubicin HCl. Cumulative incidences ranged from 0.2% at five years to 1.5% at 10 years in two separate trials involving the adjuvant treatment of women with breast cancer. These <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemias</span> generally occur within 1 to 3 years of treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	<span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> and Tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">Necrosis</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> of doxorubicin HCl can result in severe local tissue injury manifesting as <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span>, ulceration, and <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> requiring wide excision of the affected area and skin grafting. When given via a peripheral venous line, infuse doxorubicin over 10 minutes or less to minimize the risk of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> or perivenous <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>. If signs or symptoms of <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> occur, immediately terminate the injection or infusion <span class="Italics">[see <a href="#S2.3">Dosage and Administration (2.3)</a>]</span>. <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> may be present in patients who do not experience a <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> or <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span> or when blood return is present on <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> of the infusion needle. If <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> is suspected, apply ice to the site intermittently for 15 minutes, 4 times a day for 3 days. If appropriate, administer dexrazoxane at the site of <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> as soon as possible and within the first 6 hours after <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	Severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span></h2>
<p class="First">Doxorubicin HCl can cause <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>. In Study 1, the incidence of severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> was: grade 4 <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (0.3%), grade 3 <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (3%), and grade 4 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (0.1%).  A dose-dependent, reversible <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> is the predominant manifestation of hematologic toxicity from doxorubicin HCl. When doxorubicin HCl is administered every 21 days, the neutrophil count reaches its nadir 10 to 14 days after administration with recovery usually occurring by the 21st day.</p>
<p>Obtain baseline assessment of blood counts and carefully monitor patients during treatment for possible clinical complications due to <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	Use in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The clearance of doxorubicin is decreased in patients with elevated serum bilirubin with an increased risk of toxicity <span class="Italics">[see <a href="#S8.7">Use in Specific Populations (8.7)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.  Reduce the dose of doxorubicin HCl in patients with serum bilirubin levels of 1.2–5.0 mg/dL <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a>]</span>. Doxorubicin is contraindicated in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (defined as Child Pugh Class C or serum bilirubin level greater than 5 mg/dL) <span class="Italics">[see <a href="#S4">Contraindications (4)</a>].</span> Obtain liver tests including <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>, SGPT, alkaline phosphatase, and bilirubin prior to and during doxorubicin HCl therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6	<span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor Lysis Syndrome</span></h2>
<p class="First">Doxorubicin HCl may induce <span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">tumor lysis syndrome</span> in patients with rapidly growing tumors. Evaluate blood uric acid levels, potassium, calcium, phosphate, and creatinine after initial treatment. Hydration, urine alkalinization, and prophylaxis with allopurinol to prevent <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> may minimize potential complications of <span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">tumor lysis syndrome</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7	Radiation Sensitization and Radiation Recall</h2>
<p class="First">Doxorubicin HCl can increase radiation-induced toxicity to the myocardium, mucosa, skin, and liver. Radiation recall, including but not limited to cutaneous and pulmonary toxicity, can occur in patients who receive doxorubicin HCl after prior radiation therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8	Embryofetal Toxicity</h2>
<p class="First">Doxorubicin HCl can cause fetal harm when administered to a pregnant woman. Doxorubicin HCl was teratogenic and embryotoxic in rats and rabbits at doses lower than the recommended human dose.</p>
<p>If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to a fetus <span class="Italics">[see <a href="#S8.1">Use in Specific Populations (8.1)</a>]</span>.</p>
<p>Advise female patients of reproductive potential to use highly effective contraception during treatment with doxorubicin HCl and for 6 months after treatment. Advise patients to contact their healthcare provider if they become pregnant, or if pregnancy is suspected, while taking doxorubicin HCl <span class="Italics">[see <a href="#S8.1">Use in Specific Populations (8.1)</a> and <a href="#S8.6">(8.6)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in more detail in other sections of the labeling.</p>
<ul class="Disc">
<li>  <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span> and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span> <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>
</li>
<li>  Secondary Malignancies <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>
</li>
<li>  <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> and Tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">Necrosis</span> <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>
</li>
<li>  Severe <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>
</li>
<li>  <span class="product-label-link" type="condition" conceptid="4079687" conceptname="Tumor lysis syndrome">Tumor Lysis Syndrome</span> <span class="Italics">[see <a href="#S5.6">Warnings and Precautions (5.6)</a>]</span>
</li>
<li>  Radiation Sensitization and Radiation Recall <span class="Italics">[see <a href="#S5.7">Warnings and Precautions (5.7)</a>]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trial Experience in Breast Cancer</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>The safety data below were collected from 1492 women who received doxorubicin HCl at a dose of 60 mg/m<span class="Sup">2</span> and cyclophosphamide at a dose of 600 mg/m<span class="Sup">2 </span>(AC) every 3 weeks for 4 cycles for the adjuvant treatment of axillary lymph node positive breast cancer. The median number of cycles received was 4. Selected adverse reactions reported in this study are provided in Table 1. No treatment-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were reported in patients on either arm of the study. </p>
<a name="table1"></a><table width="75%">
<caption><span>Table  1. Selected Adverse Reactions in Patients with Early Breast Cancer Involving Axillary Lymph Nodes</span></caption>
<col align="left" valign="middle" width="50%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">AC<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
<th class="Rrule" align="center">Conventional CMF</th>
</tr>
<tr class="Botrule">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">N=1492</th>
<th class="Rrule" align="center">N=739</th>
</tr>
<tr class="Botrule Last">
<th class="Lrule Rrule" align="left">Adverse reactions, % of patients</th>
<th class="Rrule" align="center"></th>
<th class="Rrule" align="center"></th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Includes pooled data from patients who received either AC alone for 4 cycles, or who were treated with AC for 4 cycles followed by 3 cycles of CMF</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Grade 3 (1,000–1,999 /mm<span class="Sup">3</span>)</td>
<td class="Rrule" align="center">3.4</td>
<td class="Rrule" align="center">9.4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Grade 4 (&lt;1000 /mm<span class="Sup">3</span>)</td>
<td class="Rrule" align="center">0.3</td>
<td class="Rrule" align="center">0.3</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left">  Grade 3 (25,000–49,999 /mm<span class="Sup">3</span>)</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0.3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Grade 4 (&lt;25,000 /mm<span class="Sup">3</span>)</td>
<td class="Rrule" align="center">0.1</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">Shock</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></td>
<td class="Rrule" align="center">2</td>
<td class="Rrule" align="center">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> ≤12 hours</td>
<td class="Rrule" align="center">34</td>
<td class="Rrule" align="center">25</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> &gt;12 hours</td>
<td class="Rrule" align="center">37</td>
<td class="Rrule" align="center">12</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Intractable</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td class="Rrule" align="center">92</td>
<td class="Rrule" align="center">71</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Cardiac dysfunction</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Asymptomatic</td>
<td class="Rrule" align="center">0.2</td>
<td class="Rrule" align="center">0.1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Transient</td>
<td class="Rrule" align="center">0.1</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  Symptomatic</td>
<td class="Rrule" align="center">0.1</td>
<td class="Rrule" align="center">0</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of doxorubicin HCl. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Italics">Cardiac – </span><span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span></p>
<p><span class="Italics">Cutaneous</span> –Skin and nail hyperpigmentation, oncolysis, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, acral <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, palmar plantar erythrodysesthesia</p>
<p><span class="Italics">Gastrointestinal</span> – <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="201957" conceptname="Necrotizing enterocolitis in fetus OR newborn">necrotizing colitis</span>, <span class="product-label-link" type="condition" conceptid="4189378" conceptname="Typhlitis">typhlitis</span>, <span class="product-label-link" type="condition" conceptid="4341235" conceptname="Multiple gastric erosions">gastric erosions</span>, gastrointestinal tract <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">hematochezia</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, hyperpigmentation of the oral mucosa</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> </span>– <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span></p>
<p><span class="Italics">Laboratory Abnormalities</span> –Increased <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span>, increased <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span></p>
<p><span class="Italics">Neurological </span>– Peripheral sensory and motor <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span></p>
<p><span class="Italics">Ocular </span>– <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span> </p>
<p><span class="Italics">Vascular </span>– <span class="product-label-link" type="condition" conceptid="4107595" conceptname="Phlebosclerosis">Phlebosclerosis</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>/<span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>, <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span></p>
<p><span class="Italics">Other </span>– <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span>/<span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1	Effect of CYP3A4 Inhibitors, Inducers and P-gp</h2>
<p class="First">Doxorubicin is a major substrate of cytochrome P450 CYP3A4 and CYP2D6, and P-glycoprotein (P-gp). Clinically significant interactions have been reported with inhibitors of CYP3A4, CYP2D6, and/or P-gp (e.g., verapamil), resulting in increased concentration and clinical effect of doxorubicin. Inducers of CYP3A4 (e.g., phenobarbital, phenytoin, St. John's Wort) and P-gp inducers may decrease the concentration of doxorubicin. Avoid concurrent use of doxorubicin HCl with inhibitors and inducers of CYP3A4, CYP2D6, or P-gp.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2	Trastuzumab</h2>
<p class="First">Concurrent use of trastuzumab and doxorubicin HCl results in an increased risk of cardiac dysfunction. Avoid concurrent administration of doxorubicin and trastuzumab. The appropriate interval for administering doxorubicin following trastuzumab therapy has not been determined <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3	Paclitaxel</h2>
<p class="First">Paclitaxel, when given prior to doxorubicin HCl, increases the plasma-concentrations of doxorubicin and its metabolites. Administer doxorubicin HCl prior to paclitaxel if used concomitantly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4	Dexrazoxane</h2>
<p class="First">Do not administer dexrazoxane as a cardioprotectant at the initiation of doxorubicin HCl-containing chemotherapy regimens. In a randomized trial in women with metastatic breast cancer, initiation of dexrazoxane with doxorubicin HCl-based chemotherapy resulted in a significantly lower tumor response rate (48% vs. 63%; p=0.007) and shorter time to progression than in women who received doxorubicin HCl-based chemotherapy alone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.5"></a><a name="section-7.5"></a><p></p>
<h2>7.5 	6-Mercaptopurine</h2>
<p class="First">Doxorubicin HCl may potentiate 6-mercaptopurine-induced hepatotoxicity. In 11 patients with refractory <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> treated with 6-mercaptopurine (500 mg/m<span class="Sup">2</span> intravenously daily for 5 days per cycle every 2–3 weeks) and doxorubicin HCl (50 mg/m<span class="Sup">2</span> intravenous once per cycle every 2–3 weeks) alone or with vincristine and prednisone, all developed hepatic dysfunction manifested by elevations of total serum bilirubin, alkaline phosphatase and <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First">Pregnancy Category D</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.1"></a><p></p>
<p class="First"><span class="Italics">Risk Summary</span></p>
<p>Doxorubicin HCl can cause fetal harm when administered to a pregnant woman. Doxorubicin HCl was teratogenic and embryotoxic in rats and rabbits at doses approximately 0.07 times (based on body surface area) the recommended human dose of 60 mg/m<span class="Sup">2</span>.  If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to a fetus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.2"></a><p></p>
<p class="First"><span class="Italics">Animal Data</span></p>
<p>Doxorubicin HCl was teratogenic and embryotoxic at doses of 0.8 mg/kg/day (about 0.07 times the recommended human dose based on body surface area) when administered during the period of organogenesis in rats. <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span> and embryotoxicity were also seen using discrete periods of treatment. The most susceptible was the 6- to 9-day gestation period at doses of 1.25 mg/kg/day and greater. Characteristic malformations included esophageal and intestinal atresia, tracheo-<span class="product-label-link" type="condition" conceptid="4149721" conceptname="Esophageal fistula">esophageal fistula</span>, hypoplasia of the urinary bladder, and cardiovascular anomalies. Doxorubicin HCl was embryotoxic (increase in embryofetal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>) and abortifacient at 0.4 mg/kg/day (about 0.07 times the recommended human dose based on body surface area) in rabbits when administered during the period of organogenesis.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Doxorubicin has been detected in the milk of at least one lactating patient <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. Because of the potential for serious adverse reactions in nursing infants from doxorubicin HCl, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Based on postmarketing reports, pediatric patients treated with doxorubicin HCl are at risk for developing late cardiovascular dysfunction. Risk factors include young age at treatment (especially &lt;5 years), high cumulative doses and receipt of combined modality therapy. Long-term periodic cardiovascular monitoring is recommended for all pediatric patients who have received doxorubicin HCl. Doxorubicin HCl, as a component of intensive chemotherapy regimens administered to pediatric patients, may contribute to prepubertal growth failure and may also contribute to gonadal impairment, which is usually temporary.</p>
<p>There are no recommended dose adjustments based on age.  Doxorubicin clearance was increased in patients aged 2 years to 20 years as compared to adults, while doxorubicin clearance was similar in children less than 2 years as compared to adults <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical experience in patients who were 65 years of age and older who received doxorubicin HCl-based chemotherapy regimens for metastatic breast cancer showed no overall differences in safety and effectiveness compared with younger patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6	Females and Males of Reproductive Potential</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5.1"></a><p></p>
<p class="First"><span class="Italics">Contraception</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5.1.1"></a><p></p>
<p class="First"><span class="Underline">Females</span></p>
<p>Doxorubicin HCl can cause fetal harm when administered during pregnancy. Advise female patients of reproductive potential to use highly effective contraception during treatment with doxorubicin HCl and for 6 months after treatment. Advise patients to contact their healthcare provider if they become pregnant, or if pregnancy is suspected, while taking doxorubicin HCl <span class="Italics">[see <a href="#S8.1">Use in Specific Populations (8.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5.1.2"></a><p></p>
<p class="First"><span class="Underline">Males</span></p>
<p>Doxorubicin HCl may damage spermatozoa and testicular tissue, resulting in possible genetic fetal abnormalities. Males with female sexual partners of reproductive potential should use effective contraception during and for 6 months after treatment <span class="Italics">[see <a href="#S13.1">Nonclinical Toxicology (13.1)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5.2"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Infertility</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5.2.1"></a><p></p>
<p class="First"><span class="Underline">Females</span></p>
<p>In females of reproductive potential, doxorubicin HCl may cause <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span> and result in <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>. <span class="product-label-link" type="condition" conceptid="198715" conceptname="Premature menopause">Premature menopause</span> can occur. Recovery of menses and ovulation is related to age at treatment <span class="Italics">[see <a href="#S13.1">Nonclinical Toxicology (13.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5.2.2"></a><p></p>
<p class="First"><span class="Underline">Males</span></p>
<p>Doxorubicin HCl may result in <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">oligospermia</span>, <span class="product-label-link" type="condition" conceptid="76744" conceptname="Azoospermia">azoospermia</span>, and permanent loss of fertility. Sperm counts have been reported to return to normal levels in some men. This may occur several years after the end of therapy.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The clearance of doxorubicin was reduced in patients with elevated serum bilirubin levels. Reduce the dose of doxorubicin HCl in patients with serum bilirubin levels greater than 1.2 mg/dL <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a> and <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>.</p>
<p>Doxorubicin HCl is contraindicated in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (defined as Child Pugh Class C or serum bilirubin levels greater than 5 mg/dL) <span class="Italics">[see <a href="#S4">Contraindications (4)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Few cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> have been described. A 58-year-old man with <span class="product-label-link" type="condition" conceptid="134305" conceptname="Acute lymphoid leukemia">acute lymphoblastic leukemia</span> received 10-fold <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of doxorubicin HCl (300 mg/m<span class="Sup">2</span>) in one day. He was treated with charcoal filtration, hemopoietic growth factor (G-CSF), proton pump inhibitor and antimicrobial prophylaxis. The patient suffered <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">sinus tachycardia</span>, grade 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> for 11 days, severe <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span> and <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>. The patient recovered completely 26 days after the <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. A 17-year-old girl with <span class="product-label-link" type="condition" conceptid="4070783" conceptname="Osteosarcoma">osteogenic sarcoma</span> received 150 mg of doxorubicin HCl daily for 2 days (intended dose was 50 mg per day for 3 days). The patient developed severe <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucositis</span> on days 4–7 after the <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> on day 7. The patient was treated with antibiotics and platelets and recovered 18 days after <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Doxorubicin Hydrochloride is a cytotoxic, anthracycline, topoisomerase II inhibitor isolated from cultures of <span class="Italics">Streptomyces peucetius </span>var. <span class="Italics">caesius.  </span>Chemically, doxorubicin hydrochloride is: 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-<span class="Italics">lyx</span>o-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxylacetyl)-1-methoxy-, hydrochloride (8S-<span class="Italics">ci</span>s)-. The chemical structure of doxorubicin HCl is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=201037df-9a76-4d0b-9c2b-aba6b74e8dc2&amp;name=doxorubicin-01.jpg"></div>
<p>Doxorubicin Hydrochloride Injection, USP is a clear, red, sterile, isotonic aqueous solution provided in vials containing 10 mg/5 mL, 20 mg/10 mL, 50 mg/25 mL, 150 mg/75 mL, or 200 mg/100 mL of doxorubicin HCl. The drug product has demonstrated inherent antimicrobial activity suitable for a multiple dose presentation. Each milliliter of solution contains 2 mg of doxorubicin HCl. Inactive ingredients include sodium chloride 0.9%, USP, and water for injection, USP, quantity sufficient. The pH of the solution is adjusted to 3.0 with hydrochloric acid, USP.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The cytotoxic effect of doxorubicin HCl on malignant cells and its toxic effects on various organs are thought to be related to nucleotide base intercalation and cell membrane lipid binding activities of doxorubicin. Intercalation inhibits nucleotide replication and action of DNA and RNA polymerases. The interaction of doxorubicin with topoisomerase II to form DNA-cleavable complexes appears to be an important mechanism of doxorubicin HCl cytocidal activity.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Pharmacokinetic studies conducted in patients with various types of tumors have shown that doxorubicin follows multiphasic disposition after intravenous injection. The distribution half-life is approximately 5 minutes, while the terminal half-life is 20 to 48 hours. In four patients, doxorubicin demonstrated dose-independent pharmacokinetics across a dose range of 30 to 70 mg/m<span class="Sup">2</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Italics">Distribution</span></p>
<p>Steady-state distribution volume ranges from 809 to 1214 L/m<span class="Sup">2</span>. Binding of doxorubicin and its major metabolite, doxorubicinol, to plasma proteins is about 75% and is independent of plasma concentration of doxorubicin up to 1.1 µg/mL.</p>
<p>Doxorubicin was measured in the milk of one lactating patient after therapy with 70 mg/m<span class="Sup">2</span> of doxorubicin HCl given as a 15-minute intravenous infusion. The peak milk concentration at 24 hours after treatment was 4.4-fold greater than the corresponding plasma concentration. Doxorubicin was detectable in the milk up to 72 hours.</p>
<p>Doxorubicin does not cross the blood brain barrier.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2"></a><p></p>
<p class="First"><span class="Italics">Metabolism</span></p>
<p>Enzymatic reduction at the 7 position and cleavage of the daunosamine sugar yields aglycones which are accompanied by free radical formation, the local production of which may contribute to the cardiotoxic activity of doxorubicin HCl. Disposition of doxorubicinol in patients is formation rate limited, with the terminal half-life of doxorubicinol being similar to doxorubicin. The relative exposure of doxorubicinol, i.e., the ratio between the AUC of doxorubicinol and the AUC of doxorubicin is approximately 0.5. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.3"></a><p></p>
<p class="First"><span class="Italics">Excretion</span></p>
<p>Plasma clearance is in the range 324 to 809 mL/min/m<span class="Sup">2</span> and is predominately by metabolism and biliary excretion. Approximately 40% of the dose appears in the bile in 5 days, while only 5 to 12% of the drug and its metabolites appear in the urine during the same time period. In urine, &lt;3% of the dose was recovered as doxorubicinol over 7 days.</p>
<p>Systemic clearance of doxorubicin is significantly reduced in obese women with ideal body weight greater than 130%. There was a significant reduction in clearance without any change in volume of distribution in obese patients when compared with normal patients with less than 115% ideal body weight.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.4"></a><p></p>
<p class="First"><span class="Italics">Pediatric patients</span></p>
<p>Following administration of doses ranging from 10 to 75 mg/m<span class="Sup">2</span> of doxorubicin HCl to 60 children and adolescents ranging from 2 months to 20 years of age, doxorubicin clearance averaged 1443 ± 114 mL/min/m<span class="Sup">2</span>. Further analysis demonstrated that clearance in 52 children greater than 2 years of age (1540 mL/min/m<span class="Sup">2</span>) was increased compared with adults. However, clearance in infants younger than 2 years of age (813 mL/min/m<span class="Sup">2</span>) was decreased compared with older children and approached the range of clearance values determined in adults <span class="Italics">[see <a href="#S8.4">Use in Specific Populations (8.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.5"></a><p></p>
<p class="First"><span class="Italics">Patient Gender</span></p>
<p>There is no recommended dose adjustment based on gender. A published clinical study involving 6 men and 21 women with no prior anthracycline therapy reported a significantly higher median doxorubicin clearance in men compared to women (1088 mL/min/m<span class="Sup">2</span> versus 433 mL/min/m<span class="Sup">2</span>). However, the terminal half-life of doxorubicin was longer in men compared to women (54 versus 35 hours).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.6"></a><p></p>
<p class="First"><span class="Italics">Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span></span></p>
<p>The clearance of doxorubicin and doxorubicinol was reduced in patients with elevation in serum bilirubin <span class="Italics">[see <a href="#S2.2">Dosage and Administration (2.2)</a> and <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Doxorubicin HCl treatment results in an increased risk of secondary malignancies based on postmarketing reports <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>. Doxorubicin HCl was mutagenic in the <span class="Italics">in vitro</span> Ames assay, and clastogenic in multiple <span class="Italics">in vitro</span> assays (CHO cell, V79 hamster cell, human lymphoblast, and SCE assays) and the <span class="Italics">in vivo</span> mouse micronucleus assay.</p>
<p>Doxorubicin HCl decreased fertility in female rats at the doses of 0.05 and 0.2 mg/kg/day (approximately 0.005 and 0.02 times the recommended human dose, based on body surface area).</p>
<p>A single intravenous dose of 0.1 mg/kg doxorubicin HCl (approximately 0.01 times the recommended human dose based on body surface area) was toxic to male reproductive organs in animal studies, producing <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span>, diffuse degeneration of the seminiferous tubules, and <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">oligospermia</span>/hypospermia in rats. Doxorubicin HCl induces DNA damage in rabbit spermatozoa and dominant lethal mutations in mice.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The clinical efficacy of doxorubicin HCl-containing regimens for the post-operative, adjuvant treatment of surgically resected breast cancer was evaluated in a meta-analysis conducted by the Early Breast Cancer Trialists Collaborative Group (EBCTCG). The EBCTCG meta-analyses compared cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) to no chemotherapy (19 trials including 7523 patients) and doxorubicin HCl-containing regimens with CMF as an active control (6 trials including 3510 patients). Data from the meta-analysis of trials comparing CMF to no therapy were used to establish the historical treatment effect size for CMF regimens. The major efficacy outcome measures were disease-free survival (DFS) and overall survival (OS).</p>
<p>Of the 3510 women (2157 received doxorubicin HCl-containing regimens and 1353 received CMF treatment) with early breast cancer involving axillary lymph nodes included in the six trials from the meta-analyses, approximately 70% were premenopausal and 30% were postmenopausal. At the time of the meta-analysis, 1745 first recurrences and 1348 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> had occurred. The analyses demonstrated that doxorubicin HCl-containing regimens retained at least 75% of the historical CMF adjuvant effect on DFS with a hazard ratio (HR) of 0.91 (95% CI, 0.82–1.01) and on OS with a HR of 0.91 (95% CI, 0.81–1.03). Results of these analyses for both DFS and OS are provided in Table 2 and Figures 1 and 2.</p>
<a name="table2"></a><table width="100%">
<caption><span>Table 2. Summary of Randomized Trials Comparing Doxorubicin HCl-Containing Regimens Versus CMF in Meta-Analysis</span></caption>
<col align="left" valign="middle" width="20%">
<col align="center" valign="middle" width="16%">
<col align="right" valign="middle" width="16%">
<col align="right" valign="middle" width="16%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="16%">
<thead>
<tr class="Botrule First">
<th class="Rrule" align="center" rowspan="2">Study<br>(starting year)</th>
<th class="Rrule" align="center" rowspan="2">Regimens</th>
<th class="Rrule" align="center" rowspan="2">No. of Cycles</th>
<th class="Rrule" align="center" rowspan="2">No. of Patients</th>
<th align="center" colspan="2">Doxorubicin HCl-Containing Regimens vs. CMF<br>HR<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a> (95% CI)</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">DFS</th>
<th align="center">OS</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="6" valign="top">
<span class="Bold">Abbreviations:</span> DFS = disease free survival; OS = overall survival; AC = doxorubicin HCl, cyclophosphamide; AVbCMF = doxorubicin HCl, vinblastine, cyclophosphamide, methotrexate, 5-fluorouracil; CMF = cyclophosphamide, methotrexate, 5-fluorouracil; CMFVA = cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, doxorubicin HCl; FAC = 5-fluorouracil, doxorubicin HCl, cyclophosphamide; FACV = 5-fluorouracil, doxorubicin HCl, cyclophosphamide, vincristine; HR = hazard ratio; CI = confidence interval</td></tr>
<tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>a hazard ratio of less than 1 indicates that the treatment with doxorubicin HCl-containing regimens is associated with lower risk of disease recurrences or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> compared to the treatment with CMF.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">†</a></dt>
<dd>Includes pooled data from patients who received either AC alone for 4 cycles, or who were treated with AC for 4 cycles followed by 3 cycles of CMF.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">‡</a></dt>
<dd>Patients received alternating cycles of AVb and CMF.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Rrule" align="left" rowspan="2">NSABP B-15 <br>(1984)</td>
<td class="Rrule" align="center">AC</td>
<td class="Rrule" align="right">4</td>
<td class="Rrule" align="right">1562<a name="footnote-reference-3" href="#footnote-3" class="Sup">†</a>
</td>
<td class="Rrule" align="center" rowspan="2">0.93 (0.82–1.06)</td>
<td align="center" rowspan="2">0.97 (0.83–1.12)</td>
</tr>
<tr>
<td class="Rrule" align="center">CMF</td>
<td class="Rrule" align="right">6</td>
<td class="Rrule" align="right">776</td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="2">SECSG 2<br>(1976)</td>
<td class="Rrule" align="center">FAC</td>
<td class="Rrule" align="right">6</td>
<td class="Rrule" align="right">260</td>
<td class="Rrule" align="center" rowspan="2">0.86 (0.66–1.13)</td>
<td align="center" rowspan="2">0.93 (0.69–1.26)</td>
</tr>
<tr>
<td class="Rrule" align="center">CMF</td>
<td class="Rrule" align="right">6</td>
<td class="Rrule" align="right">268</td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="2">ONCOFRANCE<br>(1978)</td>
<td class="Rrule" align="center">FACV</td>
<td class="Rrule" align="right">12</td>
<td class="Rrule" align="right">138</td>
<td class="Rrule" align="center" rowspan="2">0.71 (0.49–1.03)</td>
<td align="center" rowspan="2">0.65 (0.44–0.96)</td>
</tr>
<tr>
<td class="Rrule" align="center">CMF</td>
<td class="Rrule" align="right">12</td>
<td class="Rrule" align="right">113</td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="2">SE Sweden BCG A<br>(1980)</td>
<td class="Rrule" align="center">AC</td>
<td class="Rrule" align="right">6</td>
<td class="Rrule" align="right">21</td>
<td class="Rrule" align="center" rowspan="2">0.59 (0.22–1.61)</td>
<td align="center" rowspan="2">0.53 (0.21–1.37)</td>
</tr>
<tr>
<td class="Rrule" align="center">CMF</td>
<td class="Rrule" align="right">6</td>
<td class="Rrule" align="right">22</td>
</tr>
<tr>
<td class="Rrule" align="left" rowspan="2">NSABC Israel Br0283<br>(1983)</td>
<td class="Rrule" align="center">AVbCMF<a name="footnote-reference-4" href="#footnote-4" class="Sup">‡</a>
</td>
<td class="Rrule" align="right">4<br>6</td>
<td class="Rrule" align="right">55</td>
<td class="Rrule" align="center" rowspan="2">0.91 (0.53–1.57)</td>
<td align="center" rowspan="2">0.88 (0.47–1.63)</td>
</tr>
<tr>
<td class="Rrule" align="center">CMF</td>
<td class="Rrule" align="right">6</td>
<td class="Rrule" align="right">50</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" rowspan="2">Austrian BCSG 3<br>(1984)</td>
<td class="Rrule" align="center">CMFVA</td>
<td class="Rrule" align="right">6</td>
<td class="Rrule" align="right">121</td>
<td class="Botrule Rrule" align="center" rowspan="2">1.07 (0.73–1.55)</td>
<td class="Botrule" align="center" rowspan="2">0.93 (0.64–1.35)</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="center">CMF</td>
<td class="Rrule" align="right">8</td>
<td class="Rrule" align="right">124</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" rowspan="2"><span class="Bold">Combined Studies</span></td>
<td class="Rrule" align="left" colspan="2">Doxorubicin HCl-Containing Regimens</td>
<td class="Rrule" align="right"><span class="Bold">2157</span></td>
<td class="Botrule Rrule" align="center" rowspan="2"><span class="Bold">0.91 (0.82–1.01)</span></td>
<td class="Botrule" align="center" rowspan="2"><span class="Bold">0.91 (0.81–1.03)</span></td>
</tr>
<tr class="Last">
<td align="center">CMF</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="right"><span class="Bold">1353</span></td>
</tr>
</tbody>
</table>
<table class="Noautorules" width="100%">
<col align="center" valign="top" width="100%">
<tbody class="Headless">
<tr><td align="center"><span class="Bold">Figure 1. Meta-analysis of Disease-Free Survival</span></td></tr>
<tr><td align="center"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=201037df-9a76-4d0b-9c2b-aba6b74e8dc2&amp;name=doxorubicin-02.jpg"></td></tr>
<tr><td align="center"><span class="Bold">Figure 2. Meta-analysis of Overall Survival</span></td></tr>
<tr><td align="center"><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=201037df-9a76-4d0b-9c2b-aba6b74e8dc2&amp;name=doxorubicin-03.jpg"></td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="S15"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<p class="First">1. "Hazardous Drugs". <span class="Italics">OSHA</span>. http://www.osha.gov/SLTC/hazardousdrugs/index.html</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><span class="Italics">Doxorubicin Hydrochloride Injection,</span> USP is a sterile parenteral, isotonic solution, available in polypropylene (CYTOSAFE)<span class="Sup">®</span> vials in single vial packs as:</p>
<dl>
<dt> </dt>
<dd>SINGLE-DOSE VIALS:<br>10 mg/5 mL (2 mg/mL) NDC 0069-4030-01<br>20 mg/10 mL (2 mg/mL) NDC 0069-4031-01<br>50 mg/25 mL (2 mg/mL) NDC 0069-4032-01</dd>
</dl>
<dl>
<dt> </dt>
<dd>Retain in carton until time of use. Discard unused portion.</dd>
</dl>
<dl>
<dt> </dt>
<dd>MULTIPLE-DOSE VIALS:<br>150 mg/75 mL (2 mg/mL) NDC 0069-4033-01<br>200 mg/100 mL (2 mg/mL) NDC 0069-4034-01</dd>
</dl>
<dl>
<dt> </dt>
<dd>Retain in carton until contents are used.</dd>
</dl>
<div class="Section" data-sectionCode="44425-7">
<a name="section-15.1"></a><p></p>
<p class="First">Store all vials at 2° to 8°C (36° to 46°F). Protect from light.</p>
<p>Storage of Doxorubicin Hydrochloride Injection under refrigerated conditions can result in the formation of a gelled product. Place gelled product at room temperature [15º to 30ºC (59º to 86ºF)] for 2 to 4 hours to return the product to a slightly viscous, mobile solution.</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-15.2"></a><p></p>
<p class="First"><span class="Italics">Handling and Disposal</span></p>
<p>Handle and dispose of Doxorubicin Hydrochloride Injection consistent with recommendations for the handling and disposal of hazardous drugs.<span class="Sup">1</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-Approved Patient Labeling (<a href="#pi">Patient Information</a>).</p>
<p>Inform patients of the following:</p>
<ul class="Disc">
<li>Doxorubicin HCl can cause irreversible myocardial damage. Advise patients to contact a healthcare provider for symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> during or after treatment with doxorubicin HCl <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</li>
<li>There is an increased risk of treatment-related <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> from doxorubicin HCl <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>.</li>
<li>Doxorubicin HCl can reduce the absolute neutrophil count resulting in an increased risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Advise patients to contact a healthcare provider for new onset <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>.</li>
<li>Doxorubicin HCl can cause fetal harm when administered during pregnancy. Advise females of reproductive potential to use effective contraception during treatment with doxorubicin HCl and for 6 months after treatment, and to contact their healthcare provider if they become pregnant, or if pregnancy is suspected, during treatment with doxorubicin HCl <span class="Italics">[see <a href="#S5.8">Warnings and Precautions (5.8)</a> and <a href="#S8.6">Use in Specific Populations (8.6)</a>]</span>.</li>
<li>Doxorubicin HCl may induce chromosomal damage in sperm, which may lead to loss of fertility and offspring with <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>. Advise patients to use effective contraception during and for 6 months after treatment <span class="Italics">[see <a href="#S5.8">Warnings and Precautions (5.8</a> and <a href="#S8.6">Use in Specific Populations (8.6)</a>]</span>.</li>
<li>Doxorubicin HCl can cause <span class="product-label-link" type="condition" conceptid="198715" conceptname="Premature menopause">premature menopause</span> in females and loss of fertility in males <span class="Italics">[see <a href="#S8.6">Use in Specific Populations (8.6)</a>]</span>.</li>
<li>Discontinue nursing while receiving doxorubicin HCl <span class="Italics">[see <a href="#S8.3">Use in Specific Populations (8.3)</a>]</span>.</li>
<li>Doxorubicin HCl can cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, mouth/<span class="product-label-link" type="condition" conceptid="4010025" conceptname="Painful mouth">oral pain</span> and sores. Advise patients to contact a healthcare provider should they develop any severe symptoms that prevent them from eating and drinking <span class="Italics">[see <a href="#S6">Adverse Reactions (6)</a>]</span>.</li>
<li>Doxorubicin HCl causes <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> <span class="Italics">[see <a href="#S6.1">Adverse Reactions (6.1)</a>]</span>.</li>
<li>Doxorubicin HCl can cause their urine to appear red for 1 to 2 days after administration.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-17"></a><p></p>
<p class="First">This product's label may have been updated. For current full prescribing information, please visit www.pfizer.com.</p>
<p><span class="Bold Italics Underline">Rx only</span></p>
<p>Distributed by<br>Pharmacia &amp; Upjohn Company<br>Division of Pfizer Inc,<br>NY, NY 10017</p>
<p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=201037df-9a76-4d0b-9c2b-aba6b74e8dc2&amp;name=doxorubicin-03a.jpg"><br>NOVAPLUS is a registered trademark of Novation LLC.</p>
<p>LAB-0637-2.0</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="pi"></a><a name="section-18"></a><p></p>
<h1>Patient Information</h1>
<p class="First"><span class="Bold">DOXORUBICIN </span>(dok-s<span class="Italics">uh</span>-<span class="Bold">roo</span>-b<span class="Italics">uh</span>-sin) <span class="Bold">HYDROCHLORIDE<br>Injection, for intravenous use</span></p>
<p><a name="important"></a><span class="Bold">What is the most important information I should know about Doxorubicin?</span></p>
<p><span class="Bold">Doxorubicin may cause serious side effects including:</span></p>
<ul class="Disc">
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span></span>. Doxorubicin may cause heart <span class="product-label-link" type="condition" conceptid="4048093" conceptname="Hamstring injury">muscle damage</span> that may lead to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, which is a condition in which the heart does not pump well. <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span> is irreversible in some cases and can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span> can happen during your treatment with Doxorubicin or months to years after stopping treatment. Your risk of heart <span class="product-label-link" type="condition" conceptid="4048093" conceptname="Hamstring injury">muscle damage</span> increases with higher total amounts of doxorubicin hydrochloride that you receive in your lifetime. Your risk of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> is higher if you:<ul class="Disc">
<li>already have other heart problems</li>
<li>have had or are currently receiving radiation therapy to your chest</li>
<li>have had treatment with certain other anti-cancer medicines</li>
<li>take other medicines that can have severe side effects on your heart</li>
</ul>
<p class="First">Tell your doctor if you get any of these symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> during or after treatment with Doxorubicin:</p>
<table class="Noautorules" width="75%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless"><tr>
<td align="left"><ul class="Disc">
<li>extreme <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></li>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span></li>
</ul></td>
<td align="left"><ul class="Disc">
<li> fast heartbeat</li>
<li> <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your feet and ankles</li>
</ul></td>
</tr></tbody>
</table>
<p>Your doctor will do tests to check the strength of your heart muscle before, during, and after your treatment with Doxorubicin.</p>
</li>
<li>
<span class="Bold">Risk of new cancers.</span> You may have an increased risk of developing certain blood cancers called acute myelogenous <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> (AML) or <span class="product-label-link" type="condition" conceptid="138994" conceptname="Myelodysplastic syndrome">myelodysplastic syndrome</span> (MDS) after treatment with doxorubicin. Talk with your doctor about your risk of developing new cancers if you take Doxorubicin.</li>
<li>
<span class="Bold">Skin damage near the vein where Doxorubicin is given (<span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reaction</span>). </span>Doxorubicin can damage the skin if it leaks out of the vein. Symptoms of infusion reaction include <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> and skin sores at injection site which may require skin grafts.</li>
<li>
<span class="Bold">Decreased blood cell counts. </span>Doxorubicin can cause a decrease in <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> (a type of white blood cells important in fighting <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>) and platelets (important for clotting and to control <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>). This may lead to a serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, the need for blood transfusions, treatment in a hospital and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Your doctor will check your blood cell count during your treatment with Doxorubicin and after you have stopped your treatment. Call your doctor right away if you get a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (temperature of 100.4 F or greater) or <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> with <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">shivering</span>.</li>
</ul>
<p><span class="Bold">What is Doxorubicin?</span></p>
<p>Doxorubicin is a prescription medicine used to treat certain types of cancers. Doxorubicin may be used alone or along with other anti-cancer medicines.</p>
<p><span class="Bold">Who should not receive Doxorubicin?</span></p>
<p><span class="Bold">Do not receive Doxorubicin if:</span></p>
<ul class="Disc">
<li>you have had a recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or have severe heart problems</li>
<li>your blood cell counts (platelets, red blood cells, and white blood cells) are very low because of prior chemotherapy</li>
<li>you have a severe liver problem</li>
<li>you have had a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to doxorubicin hydrochloride</li>
</ul>
<p><span class="Bold">What should I tell my doctor before receiving Doxorubicin?</span></p>
<p>Before you receive Doxorubicin, tell your doctor if you:</p>
<ul class="Disc">
<li>have heart problems including <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span></li>
<li>are currently receiving radiation therapy or plan to receive radiation to the chest</li>
<li>have severe liver problems</li>
<li>have had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to doxorubicin</li>
<li>have any other medical conditions</li>
<li>are pregnant or plan to become pregnant. Doxorubicin can harm your unborn baby. Women who are able to become pregnant and men who take Doxorubicin should use effective birth control (contraception) during treatment and for 6 months after treatment. Talk to your doctor about birth control methods. If you or your partner becomes pregnant, tell your doctor right away.</li>
<li>are breastfeeding or plan to breast feed. Doxorubicin can pass into your breast milk and harm your baby. You and your doctor should decide if you will receive Doxorubicin or breastfeed. You should not do both.</li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take, </span>including prescription and over-the-counter medicines, vitamins, and herbal supplements. Doxorubicin can interact with other medicines. Do not start any new medicine before you talk with the doctor that prescribed Doxorubicin.</p>
<p>Know the medicines you take. Keep a list to show your doctor and pharmacist each time you get a new medicine.</p>
<p><span class="Bold">How will I receive Doxorubicin?</span></p>
<ul class="Disc"><li>Doxorubicin will be given to you into your vein.</li></ul>
<p><span class="Bold">What are the possible side effects of Doxorubicin?</span></p>
<p><span class="Bold">Doxorubicin may cause serious side effects, including:</span></p>
<ul class="Disc"><li>See<span class="Bold"> "<a href="#important">What is the most important information I should know about Doxorubicin?</a>"</span>
</li></ul>
<p><span class="Bold">Doxorubicin may cause lower sperm counts and sperm problems in men.</span></p>
<p>This could affect your ability to father a child and cause <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>. Talk to your healthcare provider if this is a concern for you. Talk to your healthcare provider about family planning options that might be right for you.</p>
<p><span class="Bold">Irreversible <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> or early <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>. </span>Your periods (menstrual cycle) may completely stop when you receive Doxorubicin. Your periods may or may not return following treatment. Talk to your healthcare provider about family planning options that might be right for you.</p>
<p><span class="Bold">The most common side effects of Doxorubicin include:</span></p>
<ul class="Disc">
<li>Total <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">hair loss</span> (<span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>). Your hair may re-grow after your treatment.</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
</ul>
<p><span class="Bold">Other side effects: </span></p>
<ul class="Disc">
<li>Red colored urine. You may have red colored urine for 1 to 2 days after your infusion of Doxorubicin. This is normal. Tell your doctor if it does not stop in a few days, or if you see what looks like blood or blood clots in your urine.</li>
<li>Darkening of your nails or separation of your nails from your nail bed.</li>
<li>Easy <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</li>
<li>Call your doctor if you have severe symptoms that prevent you from eating or drinking, such as:<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li>mouth sores</li>
</ul>
</li>
</ul>
<p>Tell your doctor or nurse if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all of the possible side effects of Doxorubicin.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">General information about the safe and effective use of Doxorubicin.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet.</p>
<p>You can ask your pharmacist or doctor for information about Doxorubicin that is written for health professionals.</p>
<p>For more information, call 1-800-438-1985.</p>
<p><span class="Bold">What are the ingredients of Doxorubicin?</span></p>
<p><span class="Bold">Active ingredient:</span> doxorubicin hydrochloride</p>
<p><span class="Bold">Inactive ingredients for Doxorubicin Hydrochloride Injection:</span> 0.9% sodium chloride, USP, water for injection, USP, and hydrochloric acid, USP.</p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.</p>
<p><span class="Bold Italics Underline">Rx only</span></p>
<p>Distributed by<br>Pharmacia &amp; Upjohn Company<br>Division of Pfizer Inc.<br>NY, NY 10017</p>
<p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=201037df-9a76-4d0b-9c2b-aba6b74e8dc2&amp;name=doxorubicin-03a.jpg"><br>NOVAPLUS is a registered trademark of Novation LLC.</p>
<p>LAB-0638-2.0</p>
<p>02/2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 10 mg Vial Label</h1>
<p class="First">NDC 0069-4030-01<br><span class="Bold">Rx ONLY</span></p>
<p><span class="Bold">DOXOrubicin<br>Hydrochloride injection, USP</span></p>
<p><span class="Bold">Single Use Only: Discard unused portion<br>Cytosafe<span class="Sup">®</span> Vial</span></p>
<p><span class="Bold">For IV Use Only</span></p>
<p><span class="Sub">®</span><span class="Bold">N+</span></p>
<p><span class="Bold">10 mg/5 mL</span><br>(2 mg/mL)</p>
<p><span class="Bold">NOVAPLUS<span class="Sup">®</span></span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10 mg Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=201037df-9a76-4d0b-9c2b-aba6b74e8dc2&amp;name=doxorubicin-04.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-20"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 10 mg Vial Carton</h1>
<p class="First">NDC 0069-4030-01</p>
<p><span class="Bold">DOXOrubicin<br>Hydrochloride<br>injection, USP</span></p>
<p><span class="Sub">®</span><span class="Bold">N+</span></p>
<p><span class="Bold">10 mg/5 mL</span><br>(2 mg/mL)</p>
<p><span class="Bold">Single Use: Discard unused portion<br>Cytosafe<span class="Sup">®</span> Vial</span></p>
<p>For Intravenous Use Only<br><span class="Bold">Caution: Cytotoxic Agent</span></p>
<p><span class="Bold">Rx ONLY</span></p>
<p><span class="Bold">NOVAPLUS<span class="Sup">®</span></span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10 mg Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=201037df-9a76-4d0b-9c2b-aba6b74e8dc2&amp;name=doxorubicin-05.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-21"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 20 mg Vial Label</h1>
<p class="First">NDC 0069-4031-01<br><span class="Bold">Rx ONLY</span></p>
<p><span class="Bold">DOXOrubicin<br>Hydrochloride injection, USP</span></p>
<p><span class="Bold">Single Use Only: Discard unused portion<br>Cytosafe<span class="Sup">®</span> Vial</span></p>
<p><span class="Bold">For IV Use Only</span></p>
<p><span class="Sub">®</span><span class="Bold">N+</span></p>
<p><span class="Bold">20 mg/10 mL</span><br>(2 mg/mL)</p>
<p><span class="Bold">NOVAPLUS<span class="Sup">®</span></span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 20 mg Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=201037df-9a76-4d0b-9c2b-aba6b74e8dc2&amp;name=doxorubicin-06.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-22"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 20 mg Vial Carton</h1>
<p class="First">NDC 0069-4031-01</p>
<p><span class="Bold">DOXOrubicin<br>Hydrochloride<br>injection, USP</span></p>
<p><span class="Sub">®</span><span class="Bold">N+</span></p>
<p><span class="Bold">20 mg/10 mL</span><br>(2 mg/mL)</p>
<p><span class="Bold">Single Use: Discard unused portion<br>Cytosafe<span class="Sup">®</span> Vial</span></p>
<p>For Intravenous Use Only<br><span class="Bold">Caution: Cytotoxic Agent</span></p>
<p><span class="Bold">Rx ONLY</span></p>
<p><span class="Bold">NOVAPLUS<span class="Sup">®</span></span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 20 mg Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=201037df-9a76-4d0b-9c2b-aba6b74e8dc2&amp;name=doxorubicin-07.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-23"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 50 mg Vial Label</h1>
<p class="First">NDC 0069-4032-01<br><span class="Bold">Rx ONLY</span></p>
<p><span class="Bold">DOXOrubicin<br>Hydrochloride injection, USP</span></p>
<p><span class="Bold">Single Use Only: Discard unused portion<br>Cytosafe<span class="Sup">®</span> Vial</span></p>
<p><span class="Bold">For IV Use Only</span></p>
<p><span class="Sub">®</span><span class="Bold">N+</span></p>
<p><span class="Bold">50 mg/25 mL</span><br>(2 mg/mL)</p>
<p><span class="Bold">NOVAPLUS<span class="Sup">®</span></span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 50 mg Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=201037df-9a76-4d0b-9c2b-aba6b74e8dc2&amp;name=doxorubicin-08.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-24"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 50 mg Vial Carton</h1>
<p class="First">NDC 0069-4032-01</p>
<p><span class="Bold">DOXOrubicin<br>Hydrochloride<br>injection, USP</span></p>
<p><span class="Sub">®</span><span class="Bold">N+</span></p>
<p><span class="Bold">50 mg/25 mL</span><br>(2 mg/mL)</p>
<p><span class="Bold">Single Use: Discard unused portion<br>Cytosafe<span class="Sup">®</span> Vial</span></p>
<p>For Intravenous Use Only<br><span class="Bold">Caution: Cytotoxic Agent</span></p>
<p><span class="Bold">Rx ONLY</span></p>
<p><span class="Bold">NOVAPLUS<span class="Sup">®</span></span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 50 mg Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=201037df-9a76-4d0b-9c2b-aba6b74e8dc2&amp;name=doxorubicin-09.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-25"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 150 mg Vial Label</h1>
<p class="First">NDC 0069-4033-01<br><span class="Bold">Rx ONLY</span></p>
<p><span class="Bold">DOXOrubicin<br>Hydrochloride injection, USP</span></p>
<p><span class="Bold">Multidose Vial<br>Cytosafe<span class="Sup">®</span> Vial</span></p>
<p><span class="Bold">For IV Use Only</span></p>
<p><span class="Sub">®</span><span class="Bold">N+</span></p>
<p><span class="Bold">150 mg/75 mL</span><br>(2 mg/mL)</p>
<p><span class="Bold">NOVAPLUS<span class="Sup">®</span></span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 150 mg Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=201037df-9a76-4d0b-9c2b-aba6b74e8dc2&amp;name=doxorubicin-10.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-26"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 150 mg Vial Carton</h1>
<p class="First">NDC 0069-4033-01</p>
<p><span class="Bold">DOXOrubicin<br>Hydrochloride<br>injection, USP</span></p>
<p><span class="Sub">®</span><span class="Bold">N+</span></p>
<p><span class="Bold">150 mg/75 mL</span><br>(2 mg/mL)</p>
<p><span class="Bold">Multidose Vial<br>Cytosafe<span class="Sup">®</span> Vial</span></p>
<p>For Intravenous Use Only<br><span class="Bold">Caution: Cytotoxic Agent</span></p>
<p><span class="Bold">Rx ONLY</span></p>
<p><span class="Bold">NOVAPLUS<span class="Sup">®</span></span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 50 mg Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=201037df-9a76-4d0b-9c2b-aba6b74e8dc2&amp;name=doxorubicin-11.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-27"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 200 mg Vial Label</h1>
<p class="First">NDC 0069-4034-01<br><span class="Bold">Rx ONLY</span></p>
<p><span class="Bold">DOXOrubicin<br>Hydrochloride injection, USP</span></p>
<p><span class="Bold">Multidose Vial<br>Cytosafe<span class="Sup">®</span> Vial</span></p>
<p><span class="Bold">For IV Use Only</span></p>
<p><span class="Sub">®</span><span class="Bold">N+</span></p>
<p><span class="Bold">200 mg/100 mL</span><br>(2 mg/mL)</p>
<p><span class="Bold">NOVAPLUS<span class="Sup">®</span></span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 200 mg Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=201037df-9a76-4d0b-9c2b-aba6b74e8dc2&amp;name=doxorubicin-12.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-28"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 200 mg Vial Carton</h1>
<p class="First">NDC 0069-4034-01</p>
<p><span class="Bold">DOXOrubicin<br>Hydrochloride<br>injection, USP</span></p>
<p><span class="Sub">®</span><span class="Bold">N+</span></p>
<p><span class="Bold">200 mg/100 mL</span><br>(2 mg/mL)</p>
<p><span class="Bold">Multidose Vial<br>Cytosafe<span class="Sup">®</span> Vial</span></p>
<p>For Intravenous Use Only<br><span class="Bold">Caution: Cytotoxic Agent</span></p>
<p><span class="Bold">Rx ONLY</span></p>
<p><span class="Bold">NOVAPLUS<span class="Sup">®</span></span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 200 mg Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=201037df-9a76-4d0b-9c2b-aba6b74e8dc2&amp;name=doxorubicin-13.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DOXORUBICIN HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">doxorubicin hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0069-4030</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DOXORUBICIN HYDROCHLORIDE</strong> (DOXORUBICIN) </td>
<td class="formItem">DOXORUBICIN HYDROCHLORIDE</td>
<td class="formItem">2 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-4030-01</td>
<td class="formItem">1  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL, SINGLE-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050629</td>
<td class="formItem">03/05/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DOXORUBICIN HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">doxorubicin hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0069-4031</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DOXORUBICIN HYDROCHLORIDE</strong> (DOXORUBICIN) </td>
<td class="formItem">DOXORUBICIN HYDROCHLORIDE</td>
<td class="formItem">2 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-4031-01</td>
<td class="formItem">1  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10 mL in 1 VIAL, SINGLE-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050629</td>
<td class="formItem">03/05/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DOXORUBICIN HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">doxorubicin hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0069-4032</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DOXORUBICIN HYDROCHLORIDE</strong> (DOXORUBICIN) </td>
<td class="formItem">DOXORUBICIN HYDROCHLORIDE</td>
<td class="formItem">2 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-4032-01</td>
<td class="formItem">1  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">25 mL in 1 VIAL, SINGLE-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050629</td>
<td class="formItem">03/05/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DOXORUBICIN HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">doxorubicin hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0069-4033</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DOXORUBICIN HYDROCHLORIDE</strong> (DOXORUBICIN) </td>
<td class="formItem">DOXORUBICIN HYDROCHLORIDE</td>
<td class="formItem">2 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-4033-01</td>
<td class="formItem">1  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">75 mL in 1 VIAL, MULTI-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050629</td>
<td class="formItem">03/05/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DOXORUBICIN HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">doxorubicin hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0069-4034</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DOXORUBICIN HYDROCHLORIDE</strong> (DOXORUBICIN) </td>
<td class="formItem">DOXORUBICIN HYDROCHLORIDE</td>
<td class="formItem">2 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0069-4034-01</td>
<td class="formItem">1  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100 mL in 1 VIAL, MULTI-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050629</td>
<td class="formItem">03/05/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Pfizer Laboratories Div Pfizer Inc
							(134489525)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Pfizer Inc (113480771)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer (Perth) Pty Limited</td>
<td class="formItem"></td>
<td class="formItem">757868963</td>
<td class="formItem">ANALYSIS(0069-4034, 0069-4033, 0069-4032, 0069-4031, 0069-4030), API MANUFACTURE(0069-4034, 0069-4033, 0069-4032, 0069-4031, 0069-4030), MANUFACTURE(0069-4034, 0069-4033, 0069-4032, 0069-4031, 0069-4030)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Olon, SpA</td>
<td class="formItem"></td>
<td class="formItem">543029958</td>
<td class="formItem">API MANUFACTURE(0069-4034, 0069-4033, 0069-4032, 0069-4031, 0069-4030)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7bb6db49-4193-424a-baa2-00b56dae82c8</div>
<div>Set id: 201037df-9a76-4d0b-9c2b-aba6b74e8dc2</div>
<div>Version: 2</div>
<div>Effective Time: 20150121</div>
</div>
</div> <div class="DistributorName">Pfizer Laboratories Div Pfizer Inc</div></p>
</body></html>
